Issues related to pharmacy benefit management reforms. Issues related to vaccine policy. Issues related to supply chain and domestic manufacturing capacity.
2025 · 3rd Quarter (July 1 - Sep 30)
MERCK & CO. INC.
Filed by THE NICKLES GROUP, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 16, 2025
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- THE NICKLES GROUP, LLC
- Client
- MERCK & CO. INC.
- Filing UUID
- cf23c344-1b25-4051-b7f3-c8a15183e01a
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 946/S. 1862, ORPHAN Cures Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to drug pricing and pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing.
Literal federal measure citations: H.R. 946, S. 1862, H.R. 1492, H.R. 1
H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes.
Literal federal measure citations: H.R. 1
Issues related to tariffs.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.